Figure 10
From: BHLHE40, a potential immune therapy target, regulated by FGD5-AS1/miR-15a-5p in pancreatic cancer
FGD5-AS1-miR-15a-5p/miR-16-5p/miR-454-3p axis regulatory network. (A–D) Correlations between BHLHE40 expression and miR-15a-5p, miR-15b-5p, miR-16-5p and miR-454-3p in pancreatic cancer. (E–H) Analysis of miR-15a-5p, miR-15b-5p, miR-16-5p and miR-454-3p expression in pancreatic cancer and adjacent normal tissues in the TCGA database. (I–L) The expression levels of miR-15a-5p, miR-15b-5p, miR-16-5p and miR-454-3p in pancreatic cancer patients were determined by Kaplan–Meier plotter. (M) The upstream lncRNAs jointly targeted by miR-15a-5p, miR-16-5p, and miR-454-3p were predicted by bioinformatics. (N–S) Correlations between BHLHE40 expression and FGD5-AS1, HCG18, NEAT1, NUTM2B-AS1, NUTM2A-AS1 and KCNQ1OT1 in pancreatic cancer. (T) Association between FGD5-AS1 expression and pancreatic cancer patients’ outcomes.
